Companion Animals

Dog Atopy Management Progress 2026: New Treatments

Canine atopic dermatitis management has advanced significantly with biologics offering improved welfare outcomes for affected dogs.

Key Facts

Lokivetmab (Cytopoint) targets canine IL-31, the primary itch signalling molecule in dogs
Monthly injections maintain itch control with an excellent safety profile compared to steroids
Oclacitinib (Apoquel) provides rapid itch relief within 4 hours for acute flares
Dupilumab-equivalent therapies targeting IL-4/IL-13 are in development for dogs

Welfare Considerations

Chronic itch causes significant suffering and secondary self-trauma in atopic dogs. Modern biologics and targeted therapies provide sustained relief with minimal side effects compared to corticosteroids. The welfare improvement for dogs with well-controlled atopy compared to those treated with repeated steroid courses is substantial.

What You Can Do

Discuss lokivetmab or oclacitinib with your vet for dogs with ongoing atopic disease
Request dermatology referral for dogs requiring repeated steroid courses for itch control
Manage environmental triggers alongside medication for the best long-term welfare outcome